แนวทางการกากับการใช้ยา Trastuzumab ข้อบ่งใช้มะเร็งเ

แนวทางการกากับการใช้ยา Trastuzumab ข้อบ่งใช้มะเร็งเ trastuzumab Interpretation We have shown that 6-month trastuzumab treatment is non-inferior to 12-month treatment in patients with HER2-positive early trastuzumab Trastuzumab has also been shown to penetrate an impaired blood–brain barrier to a limited degree, such as during radiotherapy, and intrathecal delivery of

trastuzumab Trastuzumab injection products may cause serious or life-threatening reactions that may occur while the medication is being given or up to 24

trastuzumab Subcutaneous trastuzumab has a similar safety profile to intravenous trastuzumab and is non-inferior in terms of pharmacokinetic profile and efficacy and trastuzumab beyond progression Trastuzumab is generally well tolerated and does not cause many of the toxicities or side effects seen with conventional